Ortho

Quidel to acquire Ortho Clinical for $6B

Quidel Corporation will buy New Jersey in-vitro diagnostic specialist Ortho Clinical for $6 billion in cash and newly issued shares, per a late December announcement from the San Diego-based company.

Expected to close in the first half of 2022, the deal will allow for “top-tier R&D capabilities, a more diverse product pipeline, and broader geographic footprint,” Quidel’s CEO said in the press release.

Mentions:
Quidel, Ortho, diagnostics, M&A
Read more
Covid-19 development round-up: September 25, 2020

The state of the hunt:

Vaccine candidates from Novavax and J&J’s Janssen subsidiary entered Phase 3.
  Chinese regulators are reviewing inactivated vaccine candidates from CNBG for conditional authorization.
  Fujifilm’s flu drug Avigan (favipiravir) met its primary endpoint in a Phase 3 trial for treatment of Covid-19.

 

Vaccines

Phase 3 candidates:
 
China weighs approval of CNBG shots: State regulators are reviewing CNBG’s two…

Mentions:
Covid-19, vaccines, drugs, diagnostics, Novavax, J&J, Janssen, CNBG, Fujifilm Toyama, SII, AstraZeneca, Petrovax, CanSino, Bharat Biotech, BBIL, Codagenix, Clover Pharmaceuticals, Vector Research Center, COVAX, Gavi, Sanofi, GSK, Moderna, SiO2, ReiThera, Valneva, Endo, Technovalia, BioNet, Mymetrics, Precision Biologics, Inovio, Pfizer, Vir Biotechnology, Fiocruz, BCG, Gilead, Hovione, Ligand, ChemRar, RDIF, Relief Therapeutics, NeuroRx, Lumen Bioscience, OncoImmune, Humanigen, Thermo Fisher, SynAct Pharma, Sorrento Therapeutics, Mylan, Ortho, Luminex, Diomics, NIH, BARDA, FDA
Read more
Subscribe to Ortho